Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations
March 03 2021 - 8:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, today announced Cory Anderson has been
appointed the company’s Vice President, Clinical Affairs and
Medical Operations effective as of March 1.
“I am excited to welcome Cory to the team and know he’ll make an
impact quickly,” said Keith J. Sullivan, President and Chief
Executive Officer of Neuronetics, Inc. “We’re laser focused on
driving clinical innovation to ensure the millions suffering from
depression and other conditions have access to the treatments and
support they need, and Cory shares that commitment.”
Mr. Anderson brings over fifteen years of medical technology
experience to the company. He most recently served as Vice
President of Business Development and Marketing at Sebacia, Inc., a
medical device and aesthetics company focused on creating advanced
solutions for the treatment of dermatological conditions. As a
strategic advisor to the CEO, Mr. Anderson prioritized pipeline
business opportunities, led post-market clinical studies to drive
commercial adoption and directed Research & Development
priorities for new products and indications. Prior, Mr. Anderson
held leadership positions at The Innovation Factory and Accuitive
Medical Ventures in Atlanta. Mr. Anderson graduated from Tulane
University with a Master of Science degree in biomedical
engineering and earned his Master of Business Administration from
Goizueta Business School at Emory University. In his new role, Mr.
Anderson will report to Greg Harper, Vice President Research &
Development and Clinical.
“I’m proud to be part of the great work the Neuronetics team is
spearheading, particularly today when mental health is a more
critical issue than it has ever been,” said Mr. Anderson. “I’m
joining the team at an exciting time and am thrilled to help build
and maintain the company’s strong momentum in clinical
development.”
Inducement GrantEffective March 1, 2021, the
Compensation Committee of Neuronetics’ Board of Directors approved
restricted stock unit (“RSU”) awards representing an aggregate of
62,706 shares of its common stock to 12 new employees under the
Neuronetics, Inc. 2020 Inducement Incentive Plan, (the “2020
Inducement Plan”) in accordance with Nasdaq Listing Rule
5635(c)(4). The RSUs will vest in three substantially equal annual
installments, subject to the continuing employment of the
respective RSU recipients.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Neuronetics (or following a bona fide period of non-employment), as
an inducement material to such individuals entering into employment
with Neuronetics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing
Rules.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national
health insurance. Additional information can be found
at www.neuronetics.com.
Media Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2023 to Apr 2024